ESTEVE CDMO

ESTEVE CDMO is a global small-molecule API CDMO and advanced intermediates specializing in development and cGMP manufacturing of innovative and complex APIs, from Phase I/II programs to commercial supply. With more than 60 years of experience in small-molecule APIs, custom synthesis and advanced pharmaceutical intermediates, we provide integrated R&D, process development, analytical development, cGMP API manufacturing, technology transfer, regulatory and CMC support. Our specialized capabilities include highly potent API (HPAPI) development and manufacturing, spray drying and spray-dried dispersions (SDD), particle engineering, flow chemistry and chromatography. These technologies help address complex challenges involving solubility, bioavailability, containment, purification and scale-up. Through The Science of Collaboration, our cross-functional teams work as an extension of our customers' organizations. We identify risks early, clarify what can be accelerated, translate technical data into decisions, and provide the visibility needed to protect milestones, prepare for validation, and secure reliable supply. Our global network includes six cGMP manufacturing sites across Spain, the United States, Mexico and China, supported by more than 1,500 professionals. This network provides flexible clinical and commercial API manufacturing, local expertise, supply-chain resilience and reliable drug-substance supply throughout the product lifecycle. Headquartered in Barcelona, ESTEVE CDMO is privately held and family-owned, bringing long-term commitment and stability to every partnership. Named Most Innovative API CDMO at the 2026 CDMO Leadership Awards and Global Champion for Small-Molecule API at the 2025 CDMO Leadership Awards, we help our partners advance innovative APIs, navigate complexity and move confidently from molecule to market.